Shares of Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) hit a new 52-week low during trading on Monday . The company traded as low as $1.70 and last traded at $1.72, with a volume of 451839 shares trading hands. The stock had previously closed at $1.82.
Wall Street Analyst Weigh In
NUVB has been the topic of several recent analyst reports. HC Wainwright lowered their price objective on shares of Nuvation Bio from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 price objective (up previously from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Wedbush reiterated an "outperform" rating and set a $5.00 target price on shares of Nuvation Bio in a research note on Thursday, March 27th. Finally, Jones Trading initiated coverage on Nuvation Bio in a report on Wednesday, March 12th. They set a "buy" rating and a $10.00 target price on the stock.
Read Our Latest Stock Analysis on Nuvation Bio
Nuvation Bio Stock Performance
The firm has a market capitalization of $601.16 million, a price-to-earnings ratio of -0.82 and a beta of 1.47. The company has a fifty day moving average of $2.14 and a two-hundred day moving average of $2.45.
Institutional Trading of Nuvation Bio
Several hedge funds and other institutional investors have recently bought and sold shares of NUVB. Wealth Enhancement Advisory Services LLC acquired a new stake in Nuvation Bio during the fourth quarter worth about $27,000. Forum Financial Management LP bought a new position in shares of Nuvation Bio in the 4th quarter valued at $29,000. Cerity Partners LLC acquired a new position in shares of Nuvation Bio during the 4th quarter worth $31,000. Russell Investments Group Ltd. boosted its stake in Nuvation Bio by 15,183.7% in the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company's stock valued at $42,000 after buying an additional 15,791 shares in the last quarter. Finally, Abacus Planning Group Inc. bought a new stake in shares of Nuvation Bio during the 4th quarter valued at approximately $44,000. Institutional investors and hedge funds own 61.67% of the company's stock.
Nuvation Bio Company Profile
(
Get Free Report)
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
Recommended Stories
Before you consider Nuvation Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.
While Nuvation Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
